SAAD KHAN: Open Payments
NPI 1093707218 · CREVE COEUR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,612 in 145 payments from 18 companies in 2025. Trend: 2023 $2,805 · 2024 $2,639 · 2025 $2,612
Food & beverage: $2,612
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 17 | $283 |
| Neurocrine BioSciences, Inc. | 16 | $280 |
| Otsuka America Pharmaceutical, Inc. | 14 | $271 |
| Alkermes, Inc. | 13 | $251 |
| ABBVIE INC. | 9 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $191 |
| Axsome Therapeutics, Inc. | 9 | $171 |
| Teva Pharmaceuticals USA, Inc. | 10 | $149 |
| Corium, LLC | 9 | $143 |
| Lundbeck LLC | 5 | $124 |
Products named: REXULTI, FANAPT, INGREZZA, ARISTADA, VRAYLAR, CAPLYTA, Auvelity, Azstarys.
Industry payments across MO — which companies pay providers there.
